• Homect_img
  • About Usct_img
  • NewsRoomct_img
  • Sarah Cannon Research Institute Abstracts Accepted for Presentation at the World Conference on Lung Cancer
Required Fields *
Submit Close
Print

Let Our Family Care for Your Family!

Sarah Cannon Research Institute Abstracts Accepted for Presentation at the World Conference on Lung Cancer

June 30, 2011

NASHVILLE, TN, June 30, 2011 – The International Association for the Study of Lung Cancer (IASLC) has chosen four Sarah Cannon Research Institute (SCRI) abstracts for presentation, including a Conference President’s Selection, at the 14th World Conference on Lung Cancer, which takes place July 3-7 in Amsterdam, The Netherlands.

David R. Spigel, M.D., SCRI’s director of lung cancer research, will present findings from three of the studies in oral sessions at the meeting.

On the first study, Dr. Spigel served as primary author of the abstract that shares the promising efficacy results from a randomized phase II study (OAM4558g) evaluating MetMAb or placebo in combination with erlotinib in advanced non-small-cell lung cancer (NSCLC). The data will be presented in an oral session on Tuesday, July 5.

In addition, Dr. Spigel will chair a session called “Preclinical Models I” on Wednesday, July 6, and he will discuss the clinical findings of NK012, a nanodevice formulation, in the treatment of small-cell lung cancer during a mini oral session titled, “SCLC II”, on Thursday, July 7. Dr. Spigel will also serve as chair of this important session.

A study co-authored by Dr. Spigel, a randomized phase III trial of amrubicin vs. topotecan as second-line treatment for small-cell lung cancer (SCLC), will be presented on Monday, July 4 as part of the “Conference President’s Selection”, a session highlighting research that is particularly relevant in lung cancer research today. Dr. Spigel will present findings from the same abstract focusing on the cardiac safety of amrubicin in a separate oral session on Monday, July 4.

“Amrubicin is a novel anthracycline, a class of agents often associated with cardiac toxicity, which is being studied in a number of cancer settings,” Dr. Spigel said. “In a large phase III trial where it was compared to topotecan in patients with relapsed small-cell lung cancer, it was not associated with any cardiac toxicity. These findings are reassuring in the ongoing development of amrubicin.”

Another abstract, co-authored by Dr. Spigel, will report findings of a placebo-controlled, randomized phase II study of R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), in combination with erlotinib for advanced stage non-small-cell lung cancer (NSCLC) on Wednesday, July 6 in a session called “Medical Oncology II”.

 

Conference organizers from the International Association for the Study of Lung Cancer expect more than 7,000 medical professionals from around the world to benefit from the most up-to-date information regarding recent advances in prevention, imaging, early detection and treatment of lung cancer.

 

Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit sarahcannonresearch.com, or find us on Facebook and Twitter http://www.facebook.com/sarahcannonresearch, http://twitter.com/#!/sarahCannonPR.

Our News

View All News